Rutgers Cancer Institute, http://patch.com/new-jersey/newbrunswick/omar-boraie-chair-genomic-science-established-rutgers-cancer-institute, one of the major Cancer Institute based in New Jersey, got Omar Boraie Chair in specialized Genomic Science. It is considered that the establishment would help in developing precision medicine to address the various cancers. The chair is aimed to give best quality training and research to the scholars in developing effective treatment and medicine for cancers. It was named to Omar Boraie, the New Brunswick developer, as he donated $1.5 million to support the program. It was part of an “18 Chair Challenge” challenge by Rutgers University, as an anonymous donor contributes $1.5 million each for all the 18 chairs as each comes to $3 million.
The importance of the chair is in the wake of latest development and progress in precision medicine and treatment. The new technique ensures diagnosis and treatment of cancer at the genetic level. As this is giving individualized therapies for a better outcome, even former U.S. President Barack Obama endorsed the treatment method for better results in cancer cases. Rutgers Institute is the first institute in the country to use next-generation gene sequencing as a precision medicine approach to treating patients. The procedure is considered to be very effective for even rare cancers, where treatment is not much developed into an effective form. The development would also help to classify the cancers into subcategories according to characteristics with different genetics, to get better patient outcomes.
Omar Boraie said that he is very happy with the way the Institute is developing the precision medicine which gave positive results to patients with cancer no longer responsive. He also wonders what changes it makes when it applies to all cancer patients. He also said that he is extremely happy to be part of this great development program. Per the Newswise reports, Shridar Ganesan, MD, Ph.D., Principal Investigator of precision medicine in clinical trials and associate director for the translational science at Rutgers University Cancer Institute is named as the chairman.
With years of Oncology and research experience, Dr. Ganesan confirms that cancer is not a single disease but a collection of diseases with unique features for each. Rather than looking for the organ it affects, it is much better to do genomic analysis and classify it appropriately so that precise personalized medication can be applied. He said that he is honored to be named as the chair and hopes that the research and development would benefit even specific cancer patients with better outcomes.